Tonghua Dongbao Pharmaceutical Future Growth
Future criteria checks 1/6
Tonghua Dongbao Pharmaceutical is forecast to grow earnings and revenue by 11.7% and 12.3% per annum respectively. EPS is expected to grow by 11.6% per annum. Return on equity is forecast to be 16.3% in 3 years.
Key information
11.7%
Earnings growth rate
11.6%
EPS growth rate
Pharmaceuticals earnings growth | 17.5% |
Revenue growth rate | 12.3% |
Future return on equity | 16.3% |
Analyst coverage | Good |
Last updated | 11 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4,181 | 1,551 | N/A | 1,562 | 6 |
12/31/2025 | 3,750 | 1,371 | N/A | 1,487 | 6 |
12/31/2024 | 3,271 | 1,203 | N/A | 1,350 | 6 |
3/31/2024 | 3,001 | 1,132 | 524 | 858 | N/A |
12/31/2023 | 3,075 | 1,168 | 513 | 862 | N/A |
9/30/2023 | 2,771 | 939 | 130 | 528 | N/A |
6/30/2023 | 2,757 | 877 | 213 | 611 | N/A |
3/31/2023 | 2,556 | 1,001 | 213 | 666 | N/A |
12/31/2022 | 2,778 | 1,582 | 370 | 863 | N/A |
9/30/2022 | 2,912 | 1,643 | 565 | 1,185 | N/A |
6/30/2022 | 2,993 | 1,820 | 405 | 1,160 | N/A |
3/31/2022 | 3,332 | 1,803 | 476 | 1,163 | N/A |
12/31/2021 | 3,268 | 1,308 | 580 | 1,180 | N/A |
9/30/2021 | 3,162 | 1,242 | 654 | 1,147 | N/A |
6/30/2021 | 3,079 | 1,060 | 849 | 1,188 | N/A |
3/31/2021 | 2,996 | 989 | 854 | 1,206 | N/A |
12/31/2020 | 2,892 | 930 | 713 | 1,192 | N/A |
9/30/2020 | 2,906 | 879 | 658 | 1,054 | N/A |
6/30/2020 | 2,817 | 820 | 794 | 1,174 | N/A |
3/31/2020 | 2,781 | 815 | 856 | 1,119 | N/A |
12/31/2019 | 2,777 | 811 | 859 | 1,152 | N/A |
9/30/2019 | 2,741 | 839 | 787 | 1,109 | N/A |
6/30/2019 | 2,664 | 834 | 477 | 1,001 | N/A |
3/31/2019 | 2,688 | 838 | 139 | 1,099 | N/A |
12/31/2018 | 2,693 | 839 | 104 | 877 | N/A |
9/30/2018 | 2,701 | 876 | 263 | 938 | N/A |
6/30/2018 | 2,827 | 963 | 422 | 954 | N/A |
3/31/2018 | 2,699 | 900 | 710 | 898 | N/A |
12/31/2017 | 2,545 | 837 | N/A | 961 | N/A |
9/30/2017 | 2,414 | 789 | N/A | 900 | N/A |
6/30/2017 | 2,332 | 736 | N/A | 818 | N/A |
3/31/2017 | 2,154 | 690 | N/A | 840 | N/A |
12/31/2016 | 2,040 | 641 | N/A | 726 | N/A |
9/30/2016 | 1,909 | 604 | N/A | 687 | N/A |
6/30/2016 | 1,779 | 546 | N/A | 577 | N/A |
3/31/2016 | 1,722 | 533 | N/A | 359 | N/A |
12/31/2015 | 1,669 | 493 | N/A | 295 | N/A |
9/30/2015 | 1,661 | 450 | N/A | 248 | N/A |
6/30/2015 | 1,576 | 393 | N/A | 105 | N/A |
3/31/2015 | 1,521 | 321 | N/A | 158 | N/A |
12/31/2014 | 1,451 | 280 | N/A | 206 | N/A |
9/30/2014 | 1,369 | 215 | N/A | 142 | N/A |
6/30/2014 | 1,308 | 216 | N/A | 285 | N/A |
3/31/2014 | 1,265 | 198 | N/A | 305 | N/A |
12/31/2013 | 1,204 | 184 | N/A | 221 | N/A |
9/30/2013 | 1,141 | 119 | N/A | 290 | N/A |
6/30/2013 | 1,110 | 103 | N/A | 256 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600867's forecast earnings growth (11.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 600867's earnings (11.7% per year) are forecast to grow slower than the CN market (22.7% per year).
High Growth Earnings: 600867's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600867's revenue (12.3% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 600867's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600867's Return on Equity is forecast to be low in 3 years time (16.3%).